Data published in the August 1 issue of Pediatrics revealed that lamotrigine (LAMICTAL®) is an effective add-on therapy for the treatment of Primary Generalized Tonic-Clonic (PGTC) seizures in a subgroup of children and adolescents.
PGTC seizures (also know as "grand mal" seizures) are the most common form of generalized seizures, occurring in some 20 % of patients with epilepsy.
Currently, LAMICTAL® of GlaxoSmithKline (GSK) is not indicated for the treatment of PGTC seizures. The data published above is the first published analysis of data from a randomized, double-blind, controlled clinical trial of PGTC seizures focusing on patients age 2 to 20.
Read more at PR Newswire."PGTC seizures are more common in children than in adults, and are associated with increased risk of injury or death," said Edwin Trevathan, M.D., M.P.H., Director of the Division of Pediatric and Developmental Neurology at Washington University School of Medicine and Neurologist-in- Chief, St. Louis Children's Hospital, St. Louis, MO, key investigator of the clinical study.
"These study findings are important since physicians and neurologists continue to have limited treatment options available for generalized seizures in this age group."
.jpg)
Comment Preview